Our portfolio company NUCLIDIUM has announced the closing of its Series B extension, bringing the total round to CHF 105 million (~€114 million).

The company is developing a proprietary copper-based platform to diagnose and treat cancer, with lead programs targeting metastatic prostate cancer and metastatic breast cancer now advancing into the next phase of clinical trials.

Angelini Ventures co-led the extension as an existing investor, alongside a syndicate of leading European investors. This round also marks the entry of the European Investment Bank into NUCLIDIUM — a meaningful milestone for the company and for the broader European biotech ecosystem.

Read the full press release for more details